Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Brett M Stevens, PhD, Amanda Winters, MDPhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Ilu Kumari, M.Sc., Anuj Tyagi, M.Sc., Aftab Alam, M.Sc., Neelesh Lunkad, M.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD, Shireen Vali, PhD, Daniel A Pollyea, MD

Blood (2018) 132 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2018-99-114429

Published: 2018

Journal Articles

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Shireen Vali, PhD, Christopher R. Cogle, MD, Neeraj Arora, MD, Krishnan Shekhar, PhD, Mammen Chandy, MD, Manju Sengar, MD DM, Hasmukh Jain, MD DM, Girish Chinnaswamy, MD MRCP, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Anusha Pampana, M.Sc., Vijayashree P Shyamasundar, M.Sc., Huzaifa Sikora, B.Tech, Ansu Kumar, M.Sc., Taher Abbasi, MS, MBA, Vivek S Radhakrishnan, MDDM,MSc

Blood (2018) 132 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2018-99-116603

Published: 2018

Journal Articles

Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm

Ravi Vij, MBBS, Justin King, Mark A. Fiala, BS, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Zakir Husain, M.Tech, Anjanasree V Lakshminarayana, B.E, Anay Ashok Talawdekar, M.Tech, Upasana Mitra, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD

Blood (2018) 132 (Supplement 1): 1893.

https://doi.org/10.1182/blood-2018-99-118686

Published: 2018

Journal Articles

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow

Christopher R. Cogle, MD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Rahul K Raman, M.Sc., Robinson Vidva, B.Tech, Anuj Tyagi, M.Sc., Anay Ashok Talawdekar, M.Tech, Arko Das, M.Sc., Steven M. Kornblau, MD, Fieke W Hoff, BSc, Terzah M. Horton, MD PhD, Shireen Vali, PhD

Blood (2018) 132 (Supplement 1): 4034.

https://doi.org/10.1182/blood-2018-99-115775

Published: 2018

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Deepak Anil Lala, B.Tech, Poornachandra G, B.Tech, Saumya Radhakrishnan, B.Tech, Shivgonda C Birajdar, MCA, Ganesh Naga, B.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2018-99-115821

Published: 2018

Journal Articles

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Sirisha Narayanabhatia, M.Sc., Aktar Alam, BCA, Kunal Ghosh Roy, M.Sc., Ashish Choudhary, M.Sc., Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2018-99-114610

Published: 2018

Journal Articles

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

Aneel Paulus, MD, Prachi Jani, MD, Salman Ahmed, MD, Sonikpreet Aulakh, MD, Alak Manna, PhD, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Zakir Husain, M.Tech, Ansu Kumar, M.Sc., Pallavi Kumari, M.Sc., Anuj Tyagi, M.Sc., Taimur Sher, MD, Rami Manochakian, MD, Vivek Roy, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2018) 132 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2018-99-119574

Published: 2018

Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD

Blood (2017) 130 (Supplement 1): 1337.

https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337

Published: 2017

Journal Articles

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Neeraj Kumar Singh, B.Tech, Ansu Kumar, MS, Kabya Basu, MS, Akshita Trivedi, B.Tech, Debapriya Majumdar, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Vivek Roy, MD, Peter Martin, FRCPC, MD MS, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1260.

https://doi.org/10.1182/blood.V130.Suppl_1.1260.1260

Published: 2017

Journal Articles

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 4277.

https://doi.org/10.1182/blood.V130.Suppl_1.4277.4277

Published: 2017

Journal Articles

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

Leylah M. Drusbosky, PhD, Aneel Paulus, MD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Ansu Kumar, MS, Neeraj Kumar Singh, B.Tech, Yashaswini Ullal, BE, Priyanka Bhargav, BE, Humera Azam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 4278.

https://doi.org/10.1182/blood.V130.Suppl_1.4278.4278

Published: 2017

Journal Articles

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

Blood (2017) 130 (Supplement 1): 2707.

https://doi.org/10.1182/blood.V130.Suppl_1.2707.2707

Published: 2017

Journal Articles

A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach

Ravi Vij, MDMBA, Mark A. Fiala, BS, Mathew A. Cherian, MBBS, Neeraj Kumar Singh, B.Tech, Diwyanshu Sahu, M.Sc., Ilu Kumari, M.Sc., Ankitha Narayan, B.E, Poornachandra G, B.Tech, Shireen Vali, PhD, Taher Abbasi, MS, MBA

Blood (2017) 130 (Supplement 1): 2978.

https://doi.org/10.1182/blood.V130.Suppl_1.2978.2978

Published: 2017

Journal Articles

Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Leylah M. Drusbosky, PhD, Salah-Eddin Komrokji, Najla Al Ali, M.Sc, Neeraj Kumar Singh, B.Tech, Chandan Kumar, MT, Sumanth Vasista, BE, Diwyanshu Sahu, M.Sc., Ganesh Naga, BT, Patil Dattatraya, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, David A Sallman, MD, Rami S. Komrokji, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2954.

https://doi.org/10.1182/blood.V130.Suppl_1.2954.2954

Published: 2017

Journal Articles

Predictive Simulation Modeling in JAK2-Mutant MPNs Identified Ruxolitinib and Sorafenib As a Synergistic Drug Combination for Disease Modifying Therapy

Peter P. Sayeski, PhD, Leylah M. Drusbosky, PhD, Neeraj Kumar Singh, B.Tech, Anusha Pampana, Shahabuddin Usmani, MS, Mohammed Sauban, BE, Abha Kushwaha, Anu Ramakrishnan, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 5287.

https://doi.org/10.1182/blood.V130.Suppl_1.5287.5287

Published: 2017

NARROW

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing

A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach

Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Predictive Simulation Modeling in JAK2-Mutant MPNs Identified Ruxolitinib and Sorafenib As a Synergistic Drug Combination for Disease Modifying Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only